Pending — not yet graded
“Bullish on Glenmark Pharmaceuticals, recommending a buy with a target price of ₹2,470 and a stop loss of ₹2,260. The stock retested a falling supply trendline breakout and formed a bullish Marubozu candle, with momentum indicators positively placed, suggesting strong momentum above ₹2,350.”
Chandan Taparia’s track record: 3 graded calls · 95% CI 0–56%
Glenmark PharmaceuticalsBullishCalled 21 Aug 2026
This call hasn't reached its evaluation window yet — the HIT/MISS verdict will appear here once it's graded against real price data. Save it above to find it again from your profile.